|Year : 2016 | Volume
| Issue : 2 | Page : 49-52
Scleromyxedema without internal malignancy – A case report and review
PK Shekhat1, R Mahajan2, IA Pandya1, FE Bilimoria3
1 Resident, Department of Skin & VD, Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, Piparia, Waghodia, Vadodara, Gujarat, India
2 Associate Professor, Department of Skin & VD, Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, Piparia, Waghodia, Vadodara, Gujarat, India
3 Professor & HOD, Department of Skin & VD, Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, Piparia, Waghodia, Vadodara, Gujarat, India
|Date of Web Publication||30-Aug-2018|
P K Shekhat
Resident, Department of Skin & VD, Smt. B. K. Shah Medical Institute and Research Center, Sumandeep Vidyapeeth, Piparia, Waghodia, Vadodara, Gujarat
Source of Support: None, Conflict of Interest: None
Scleromyxedema is a chronic, progressive condition characterized by confluent lichenoid eruption. It is usually associated with paraproteinemia. We present the case of 52 years old man diagnosed scleromyxedema without malignancy and paraproteinemia and treated with oral methotrexate and betamethasone.
Keywords: Scleromyxedema, Malignancy
|How to cite this article:|
Shekhat P K, Mahajan R, Pandya I A, Bilimoria F E. Scleromyxedema without internal malignancy – A case report and review. J Integr Health Sci 2016;4:49-52
|How to cite this URL:|
Shekhat P K, Mahajan R, Pandya I A, Bilimoria F E. Scleromyxedema without internal malignancy – A case report and review. J Integr Health Sci [serial online] 2016 [cited 2023 Feb 5];4:49-52. Available from: https://www.jihs.in/text.asp?2016/4/2/49/240203
| Introduction|| |
Scleromxyedema is rare disease affecting men and women. It is chronic progressive condition characterized by dermal fibrosis and mucinosis. It is almost always associated with monoclonal paraproteinemia usually immunoglobulin G type. Herein we present the case of a 52 years old man with classical cutaneous features of scleromyxedema. This was confirmed by H&E (Hematoxylin and eosin stain) and special stain through skin biopsy. However no evidence of malignancy was obtained in spite of intensive investigations. This case is being presented due to the rare occurrence of scleromyxedema in absence of malignancy.
| Case Report|| |
A 52 years old male patient presented with history of skin lesions all over body and progressive tightening of skin over face and body since 10-12 years. He gave history of difficulty in mouth opening and difficulty in swallowing. However there was no history of photosensitivity, Raynaud’s phenomenon, muscle weakness or weight loss. The patient had received multiple treatments since the last 3-4 months to no avail. On examination, skin over face showed waxy translucent papules with loss of lateral one third of bilateral eyebrows. Waxy papules seen over upper back, bilateral retroauricular area and pinnae, [Figure 1]a resulting in stony hard feel of both pinnae. [Figure 1]b Skin was taut to touch with mouth opening reduced to two fingers. There was diffuse tightening of skin underlying the papules over the entire trunk. [Figure 2] a Loose folds of skin were seen over bilateral axilla, back, and groin. [Figure 2]b Patient was unable to flex the fingers of both hands due to tightening of skin over dorsum of both hands. There were no stellate ulcers, neither any evidence of calcinosis. Nail discoloration and nail dystrophy was seen over toe nails. Differential diagnosis considered was lepromatous leprosy, scleredema, nephrogenic systemic fibrosis, systemic sclerosis, sarcoidosis, and granular annulare. Routine investigations including LFT were within normal limits (HB: - 10.2g/dl, TC 5200/cumm, RBS 154mg/dl, blood urea 42 mmol/L, creatinine 1.1 mg/dl). Chest x ray and USG (abdomen and pelvic) were normal. ELISA for HIV was negative. Serum protein electrophoresis (using agarose gel electrophoresis by Helena) showed normal levels of serum protein bands (gamma 1.28 g/dl, albumin 3.75 g/dl alpha-1 0.28 g/dl, alpha-2 0.82, beta 0.80g/dl). Histopathology revealed thinned out epidermis along with deposition of mucin in upper and mid reticular dermis accompanied by widespread proliferation of fibroblasts. This was confirmed by alcian blue staining.
|Figure 1: (a) waxy translucent papules in retroauricular region (b) taut shiny skin with waxy papules over the fore head|
Click here to view
|Figure 2: (a) waxy papules over nape of neck and upper back (b) increased folds of skin in upper lateral and lower trunk|
Click here to view
| Discussion|| |
Scleromyxedema is rare chronic and progressive disease. Middle age adults are usually affected. Its classical clinical features include generalized symmetric eruption of firm waxy papules on the upper trunk, extremities, neck, face and ears, occasionally resembling leonine facies of leprosy.
|Figure 3: (a) Thinned out epidermis, deposition of mucin in upper and mid reticular dermis (b) Mucin deposition, proliferation of fibroblasts|
Click here to view
Multiple systemic disorders such as neurological, cardiac, ophthalmological disorders, renal, muscular (proximal myopathy), gastrointestinal (esophageal dysmotility), and pulmonary are frequent associations. All of these together may result in severe disability and may be fatal in some cases. It never affects mucous membranes and rarely affects the scalp. It is also known as the Arndt-Gottron syndrome or generalized lichen myxedematosus.
Paraproteinemia is most common feature of Scleromyxedema. In 80% patients, monoclonal gammopathy is IgG with lambda light chains type. Atypical cases of lichen myxedematosus have been reported with absence of monoclonal gammopathy, albeit with the plethora of cutaneous and systemic clinical signs.
Diagnostic criteria for scleromyxedema
- Generalized papular eruption and sclerodermoid features
- Microscopic triad of mucin deposition, fibroblast proliferation and fibrosis
- Monoclonal gammopathy
- Absence of thyroid disorder
- Diffuse dermal mucin deposition
- Increased collagen
- Numerous irregularly shaped fibroblasts
|Table 1: Rongioletti’s proposed classification for scleromyxoedema in 2006|
Click here to view
Histopathology of scleromyxedema shows extensive proliferation of fibroblasts throughout the dermis with irregularly arranged collagen bundles. Collagen bundles are split by mucin. Amount of mucin is greater in the upper half than in the lower half of the dermis. Both scleromyxedema and nephrogenic fibrosing dermopathy are characterized by a dermal infiltrate of spindle cells with increased mucin and collagen, so it is difficult to distinguish scleromyxedema from nephrogenic fibrosis.
Treatment of the scleromyxedema is disappointing inspite of significant advances in understanding disease pathogenesis. Many treatment options have been described in literature with limited efficacy. Among the various treatments described are topical and systemic corticosteroids(daily or pulsed dose), psoralen combined with ultraviolet A (PUVA), oral retinoids, chloroquine, methotrexate, thalidomide, IVIG, interferon-α and cyclosporine. Therapeutic procedures such as plasmapheresis, radiotherapy, autologous stem cell transplantation, extracorporeal photochemotherapy have also been tried. A combination of BCNU, etoposide, cytarabine and melphalan (BEAM regime) has been recommended prior to autologous stem cell transplantation. Our patient was started on tab methotrexate 7.5 mg/week and betamethasone 0.5 mg (6tab/week). The patient reported mild improvement in sensation of tightness over face and shoulders after 3 months of treatment, however cutaneous lesions were persistent.
| References|| |
Salas-Alanis JC, Martinez-Jaramillo B, Gomez- Flores M, Ocampo-Candiani J. Scleromyxedema, a therapeutic dilemma. Indian journal of dermatology. 2015 Mar;60(2):215.
Abarzúa AA, Giesen LF, Sandoval MO, González SB. Scleromyxedema without paraproteinemia. International journal of dermatology. 2014 Aug 1;53(8):971-4.
Thomas E, George A, Deodhar D, John M. Scleromyxedema: An atypical case. Indian journal of dermatology. 2015 May 1;60(3):323.
Koregol S, Yatagiri RV, Warad SR, Itagi NR. A rare association of scleromyxedema with cutis verticis gyrata. Indian dermatology online journal. 2016 May;7(3):186.
Maize J, Maize J, Metcalf J. Metabolic Diseases Of The Skin. In: Elder D, Ed. By. Lever’s Histopathology Of The Skin. 10th Ed. New Delhi: Lippincott Williams & Wilkins; 2009. P. 444.
Mehta V, Balachandran C, Rao R. Arndt Gottron scleromyxedema: successful response to treatment with steroid minipulse and methotrexate. Indian journal of dermatology. 2009 Apr 1;54(2):193.
Guarenti I, Sebastiani V, Pinto G, de Souza PR, de Almeida H. Successful treatment of scleromyxedema with oral thalidomide. International journal of dermatology. 2013 May 1;52(5):631-2.
Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. InSeminars in arthritis and rheumatism 2008 Dec 31 (Vol. 38, No. 3, pp. 188-194). WB Saunders.
Saigoh S, Tashiro A, Fujita S, Matsui M, Shibata S, Takeshita H, Duan H, Moroi Y, Urabe K, Koga T, Furue M. Successful treatment of intractable scleromyxedema with cyclosporin A. Dermatology. 2004 Jan 29;207(4):410-1.
Açikgöz G, Özmen I, Hüseynov S, Gamsizkan M, Çaliskan E, Arca E, Koç E. A case of atypical scleromyxedema without gammopathy treated with cyclosporine. Indian Journal of Dermatology, Venereology, and Leprology. 2014 May 1:80(3):278.
[Figure 1], [Figure 2], [Figure 3]
[Table 1], [Table 2]